To mark HIV Vaccine Awareness Day on 18 May, the Journal of the International AIDS Society (JIAS) has published a viewpoint, titled “How Vaccinating People Living With HIV May Guide bNAb‑Based Vaccines”, authored by Penny L. Moore, Leonidas Stamatatos and Alexandra Trkola.
Despite major advances in HIV treatment and prevention, an effective HIV vaccine remains a critical global priority. Recent trials have shown promise, demonstrating that broadly neutralizing antibodies (bNAbs) can successfully prevent acquisition of certain HIV strains. However, inducing fully matured bNAbs and evaluating vaccine efficacy in traditional trials limited to HIV-negative individuals remains time intensive, complex and costly.
In this viewpoint, the authors propose expanding bNAb-focused vaccine trials to include people living with HIV. They argue that the primed immune landscape of this population, shaped by prior viral replication and diversity, may create an opportunity to accelerate the development of both preventive and therapeutic HIV vaccines.
Access the viewpoint here.
Source : JIAS
Related HIV and Co-Infections News
-
HIV i-Base: New study predicts that PrEP efficacy in men is driven by drug levels in cells: matching earlier results in women
-
[Publications] CHAI: Lenacapavir and long-acting HIV PrEP: flash market update and spotlights across early adopters
-
IAVI: HIV Vaccine Awareness Day 2026: African research leading the charge
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.